Cargando…

Rare but Serious: Ibrutinib Induced Liver Failure

Detalles Bibliográficos
Autores principales:	Kleijwegt, Fleur S., Roda, Afnan Abdul, Rolvink, José, Kater, Arnon P., Kersten, Marie José, Vos, Josephine M.I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924548/ https://www.ncbi.nlm.nih.gov/pubmed/31976481 http://dx.doi.org/10.1097/HS9.0000000000000307

Ejemplares similares

The effect of a Clinical Decision Support System on the frequency of dose adjustments of anticancer drugs in case of renal or hepatic dysfunction
por: Rolvink, José, et al.
Publicado: (2021)

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
por: de Weerdt, Iris, et al.
Publicado: (2017)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

Ibrutinib‐induced severe liver injury
por: Nandikolla, Amara G., et al.
Publicado: (2017)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
por: Kielbassa, Karoline, et al.
Publicado: (2023)

1092. Increased Risk of Serious Infections in Mantle Cell Lymphoma Versus Other Hematologic Malignancies in Patients on Ibrutinib
por: Holowka, Thomas, et al.
Publicado: (2020)

1095. Investigation of Risk Factors Associated with Serious Bacterial, Viral and Invasive Fungal Infections in Hematologic Patients on Ibrutinib
por: Holowka, Thomas, et al.
Publicado: (2020)

Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature
por: Choi, Goda, et al.
Publicado: (2008)

Reversible Systolic Heart Failure in a Patient on Ibrutinib Chemotherapy
por: Khaja, Misbahuddin, et al.
Publicado: (2022)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
por: Kater, Arnon, et al.
Publicado: (2023)

A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome
por: Ozturk, Erman, et al.
Publicado: (2021)

Electrocardiographic Changes Associated With Ibrutinib Exposure
por: Fradley, Michael G., et al.
Publicado: (2020)

T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
por: Peters, Fleur S., et al.
Publicado: (2021)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Bland-White-Garland syndrome – a rare and serious cause of failure to thrive
por: Szmigielska, Agnieszka, et al.
Publicado: (2013)

An abdominal mass with thrombosis due to inferior vena cava agenesis mimicking lymphoma
por: Weijmans, Maaike, et al.
Publicado: (2021)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

SAT-593 Thyrotoxic Heart Disease: Rare but Serious Manifestation of Congestive Heart Failure
por: Petrenko, Olesya, et al.
Publicado: (2019)

IgM monoclonal gammopathies of clinical significance: diagnosis and management
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Dutch Physician’s Perspectives on Diagnosis and Treatment of Waldenström’s Macroglobulinemia Before and After the Implementation of a National Guideline
por: Amaador, Karima, et al.
Publicado: (2022)

Ibrutinib: Rebound effect in the form of respiratory deterioration following the discontinuation of ibrutinib: case report
Publicado: (2021)

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
por: Karvaly, Gellért Balázs, et al.
Publicado: (2022)

Pancytopenia in Carbamazepine Therapy: A Rare and Serious Entity with Simple Prevention
por: Bhardwaj, Akansha, et al.
Publicado: (2023)

Ibrutinib for B cell malignancies
por: Novero, Aileen, et al.
Publicado: (2014)

Ibrutinib-Induced Skin Rash
por: Kirar, Sudhir, et al.
Publicado: (2021)

Ibrutinib: Pneumonitis: case report
Publicado: (2021)

Arrhythmia Patterns in Patients on Ibrutinib
por: Fazal, Muhammad, et al.
Publicado: (2022)

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
por: Levin, Mark-David, et al.
Publicado: (2020)

Sclerosing epithelioid fibrosarcoma: rare and serious
por: Yahyaoui, Mounir, et al.
Publicado: (2020)

Patient preferences regarding treatment options for Waldenström's macroglobulinemia: A discrete choice experiment
por: Amaador, Karima, et al.
Publicado: (2022)

Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
por: Allouchery, Marion, et al.
Publicado: (2021)

Targets for Ibrutinib Beyond B Cell Malignancies
por: Berglöf, A., et al.
Publicado: (2015)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Late-chronic cardiotoxicity and heart failure caused by ibrutinib: a case report and literature review
por: ZHU, Jian, et al.
Publicado: (2021)

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
por: Urban, Aleksandra, et al.
Publicado: (2023)

Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
por: Zerbit, Jeremie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_99o7sggbj4d7dkr7o8n1q88k9k